<DOC>
	<DOCNO>NCT01067326</DOCNO>
	<brief_summary>We study hypothesis long-term Tekturna treatment improve endothelial function production function endothelial progenitor cell ( EPCs ) patient early atherosclerosis . Specifically , long-term Tekturna treatment increase Reactive Hyperemia Peripheral Arterial Tonometry index increase number function circulate endothelial progenitor cell , compare placebo , association reduction inflammation oxidative stress .</brief_summary>
	<brief_title>The Effect Tekturna Endothelial Function Endothelial Progenitor Cells Patients With Early Atherosclerosis</brief_title>
	<detailed_description>Aliskiren direct renin-inhibitor may beneficial effect vascular endothelium , similar antihypertensive therapy target renin-angiotensin-aldosterone system ( RAAS ) . The current study design test hypothesis aliskiren improve endothelial function increase number endothelial progenitor cell ( EPCs ) normotensive patient early atherosclerosis .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>1 . Age &gt; 18 year old 2 . More two follow cardiovascular risk factor ( determine prescreen phone call ) : family history cardiovascular disease , physical inactivity/sedentary lifestyle , obesity overweight , family history diabetes mellitus hypertension , total cholesterol &gt; 200 mg/dL , LDL &gt; 130 mg/dL , HDL &lt; 50 mg/dL , smoking , stress , Triglycerides &gt; 150 mg/dL 3 . Demonstrated endothelial dysfunction ( reactive hyperemia EndoPAT score &lt; 2.0 ) time screen 1 . Serum potassium &gt; 5.0 mmol/L document time prior study 2 . History cardiovascular event ( stroke , transient ischemic attack ( TIA ) , myocardial infarction ( MI ) , unstable angina , coronary artery bypass grafting ( CABG ) , percutaneous coronary intervention , hospitalization due heart failure ) 3 month prior study 3 . Hypertension hypotension ( Randomization ) : patient Mean Seated Systolic Blood Pressure ( msSBP ) ≥ 170 mmHg , msSBP &lt; 100 mmHg Mean Seated Diastolic Blood Pressure ( msDBP ) ≥ 110 mmHg 4 . Congestive heart failure New York Heart Association ( NYHA ) class III IV 5 . Concomitant treatment two ( 2 ) reninangiotensinaldosterone system block agent , e.g . Angiotensin Converting Enzyme Inhibitor ( ACEI ) , Angiotensin II receptor blocker ( ARB ) aldosteroneantagonist 6 . Unstable serum creatinine 7 . Second ( II ) third ( III ) degree heart block without pacemaker 8 . Concurrent potentially life threaten arrhythmia uncontrolled arrhythmia 9 . Clinically significant valvular heart disease 10 . Known renal artery stenosis 11 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug include , limited , follow : History major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection Any history pancreatic injury , pancreatitis evidence impair pancreatic function/injury indicate abnormal lipase amylase Evidence hepatic disease determine history hepatic encephalopathy , history cirrhosis , esophageal varix , history portocaval shunt 12 . History malignancy basal cell skin cancer within past five year 13 . Any concurrent life threaten condition life expectancy le 2 year 14 . History evidence drug alcohol abuse within last 12 month 15 . Any surgical medical condition , opinion investigator , may place patient high risk his/her participation study , likely prevent patient comply requirement study complete study 16 . History hypersensitivity study drug medication belong therapeutic class study drug well know suspect contraindication study drug 17 . History noncompliance medical regimen unwillingness comply study protocol 18 . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer 19 . Any condition opinion investigator would jeopardize evaluation efficacy safety 20 . Persons directly involved execution protocol 21 . Pregnant nursing ( lactate ) woman 22 . Women ChildBearing Potential ( WOCBP ) unless postmenopausal least one year , surgically sterile use effective method contraception define local Health Authorities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Endothelial Dysfunction</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Tekturna</keyword>
	<keyword>Endothelial Peripheral Arterial Tomography ( EndoPAT )</keyword>
	<keyword>Progenitor Cells</keyword>
	<keyword>renin inhibition</keyword>
	<keyword>endothelial progenitor cell</keyword>
	<keyword>early atherosclerosis</keyword>
</DOC>